Medical/Pharmaceuticals
LISCure Biosciences Secures World's First Regulatory Approval for Hair Health Probiotic as an functional Ingredient
SEONGNAM, South Korea, March 20, 2025 /PRNewswire/ -- LISCure Biosciences Inc. ("LISCure") announced on the2025 Feb that it has received approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Mobiome®, a proprietary probiotic ingredient developed to promote hair health. Securing th...
2025-03-20 21:00
2126
TiumBio's Partner Hansoh Pharma Expands Indications for Merigolix (HS-10518) with Initiation of ART (Assisted Reproductive Technology) Development
* Clinical Trial Approval of merigolix (TU2670, HS-10518) for the inhibition of premature LH (luteinizing hormone) surges in women undergoing COS (controlled ovarian stimulation) inChina SEONGNAM, South Korea, March 20, 2025 /PRNewswire/ -- TiumBio (KOSDAQ: 321550), a clinical-stage biopharmace...
2025-03-20 20:00
1865
Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer
* Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL * The combination of golidocitinib and PD-1 antibody showed synergistic anti-tumor effects in anti-PD-1-resistant NSCLC SHANGHAI, March 20, 2025 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmac...
2025-03-20 18:00
1803
111, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results
* Achieved First-Ever Annual Operating Profit * Bottom Line Improved by RMB332.7 Million YoY in 2024 * Operating Expenses as a Percentage of Revenues Decreased 230 Basis Points YoY in 2024 * Q4'24 Operating Expenses as a Percentage of Revenues Decreased 470 Basis Points YoY * Achieved Fi...
2025-03-20 13:00
3732
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T‑Cell Therapy Development
CRANBURY, N.J., March 19, 2025 /PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology ...
2025-03-19 22:00
2079
Jacobio Pharma Announces 2024 Annual Results
BEIJING, SHANGHAI and BOSTON, March 19, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) released its 2024 annual results, with revenue of RMB160 million, R&D expense ofRMB330 million. Major operating and financing activities generated RMB320 million cash inflows. By the end of 2024, cash and bank b...
2025-03-19 21:42
3652
"Miracle Doctor" Dr. Wei-Hua Chen: Role of Oligo Fucoidan in Cancer Care
LOS ANGELES, March 19, 2025 /PRNewswire/ -- Dr. Wei-Hua Chen, a renowned 70-year-old cardiologist and the director of Hongxin Clinic (Taichung,Taiwan), has been awarded the "28th Fervent Global Love of Lives Award 2025" by the Chou Ta-Kuan Cultural and Educational Foundation. First diagnosed with...
2025-03-19 20:00
1380
CARsgen Announced 2024 Annual Results
SHANGHAI, March 18, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced its 2024 Annual Results. Business Highlights * Zevor-cel was approved by China's National Medical Products Administra...
2025-03-19 08:15
3357
Vatech and Pearl Join Forces to Revolutionize Dental Diagnosis with AI Integration
HWASEONG, South Korea, March 18, 2025 /PRNewswire/ -- Vatech, a global leader in dental imaging solutions, and Pearl, a frontrunner in dental AI technology, have announced a collaborative alliance aimed at transforming the landscape of dental diagnosis. By integrating Pearl's advanced AI-powered ...
2025-03-18 21:00
1884
Lunit Secures Multi-Year Contract with UAE's Largest Healthcare Network to Power National AI Breast Cancer Screening Program
Strategic agreement to deploy Lunit INSIGHT MMG across SEHA's extensive healthcare network, analyzing over hundred thousand mammograms over five years SEOUL, South Korea, March 18, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and t...
2025-03-18 21:00
2992
A chronographic analysis of MSC's rollercoasting journey
TIANJIN, China, March 18, 2025 /PRNewswire/ -- On March 12, 2025, China's Center for Drug Evaluation (CDE) approved Tasly's Investigational New Drug (IND) application for NR-20201, an allogeneic adipose-derived mesenchymal stromal cell, sparking discussions about the historical development of me...
2025-03-18 20:00
1969
So-Young Reschedules Release of Fourth Quarter and Full Year 2024 Financial Results to March 28, 2025
BEIJING, March 18, 2025 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the largest and most vibrant social community inChina for consumers, professionals and service providers in the medical aesthetics industry, today announced that it has rescheduled the ...
2025-03-18 17:00
2699
Cipla and Formosa sign multi-regional licensing deal for Clobetasol Suspension
This partnership aims to enhance ophthalmic care by providing better treatment for post-operative inflammation and pain in patients across 11 countries. TAIPEI, March 18, 2025 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals (6838.TW) today announced an exclusive licensing agreement with Cipl...
2025-03-18 16:00
1642
TaiMed Biologics Announces Results from Late-Breaking Phase 2a Data on Long-Acting HIV Maintenance Therapy at CROI 2025
TMB-365/TMB-380 Combination Demonstrates Viral Suspension Without the Need for Susceptibility Screening TaiMed Biologics will reshape HIV treatment management and seeks strategic collaborations with global pharmaceutical partners for the commercialization of its long-acting HIV maintenance thera...
2025-03-18 06:00
1895
Galux Unveils a Study in AI-Powered De Novo Antibody Design for Multiple Therapeutic Targets
* Pioneering AI technology successfully designs antibodies de novo for six therapeutic targets, including one without an experimentally resolved structure SEOUL, South Korea, March 17, 2025 /PRNewswire/ -- Galux Inc., a South Korean startup specializing in AI-driven protein therapeutics design,...
2025-03-17 21:00
1810
NEXTBIOMEDICAL, Fast Resorbable Microsphere 'Nexsphere-F' : Clinical Study Results on 155 Patients Published in the JVIR
* Safety and Excellent Pain Relief Effect after Musculoskeletal Pain Embolization SEOUL, South Korea, March 17, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LDT, announced that clinical study results of Nexsphere-F™, a resorbable embolic agent for treating joint pain, have been published in the est...
2025-03-17 21:00
2086
WuXi AppTec Revenue and Profit Achieved Steady QoQ Growth in 2024, Meeting Full-year Guidance; Q4 Revenue and Profit Both Reached Record Highs
* Fourth-Quarter Revenue Reached RMB11,539 Million, Up 6.9% Year-over-Year * 2024 Revenue Reached RMB39,241 Million, Up 5.2% Year-over-Year (Excluding COVID-19 Commercial Project of 2023) * Full-Year Net Profit Attributable to the Owners of the Company Reached RMB9,450 Million[1], Diluted Ea...
2025-03-17 20:19
2985
Chance Pharma Secures New Funding to Accelerate Development of Innovative Inhalation Therapies
HANGZHOU, China, March 17, 2025 /PRNewswire/ -- Chance Pharmaceuticals ("Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced the successful completion of a new round of financing. Heda Health Fund an...
2025-03-17 18:00
2007
Fangzhou Inc.'s H2H Smart Healthcare Platform Honored as one of Guangdong's Premier High-Tech Innovation Products
GUANGZHOU, China, March 17, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, today announced that its proprietary "H2H Smart Healthcare Innovation Platform" has been distinguished as a "2024Guangdong Province Premier High-Qual...
2025-03-17 15:43
1814
Akeso's Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer
HONG KONG, March 16, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) announced that its innovative, self-developed anti-PD-1 monoclonal antibody, penpulimab, has been officially approved by the National Medical Products Administration (NMPA) for the first-line treatment of recurrent or metastatic nasop...
2025-03-17 11:49
1966
Week's Top Stories
Most Reposted
Nine Years of Impact: JULO Disburses USD 1.7 Billion in Digital Financing Across Indonesia
[Picked up by 297 media titles]
2025-12-23 14:23
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 277 media titles]
2025-12-26 12:55Fijian and Chinese Scholars Gather to Discuss Bilateral Friendship and the Outlook for APEC 2026
[Picked up by 264 media titles]
2025-12-22 15:56
"Nihao China" App Launches as an All-in-One Solution for International Visitors
[Picked up by 253 media titles]
2025-12-24 17:54Sobot Shines in G2 Winter 2026: A New Benchmark in AI Customer Service
[Picked up by 252 media titles]
2025-12-24 10:00